NCT04619303 - Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2017

Primary Completion Date

February 14, 2020

Study Completion Date

February 14, 2020

Conditions

Diabetic Macular EdemaDiabetic Retinopathy

Interventions

DRUG

Dexamethasone intravitreal implant

Intravitreal injection of 0.7mg dexamethasone implant

DRUG

Bevacizumab Injectable Product

Invtravitreal injection of 1.25mg/0.05mL bevacizumab

Trial Locations (13)

Derbarl Yerrigan Health Service Inc., Perth

Lions Eye Institute Nedlands, Perth

Lions Eye Institute Midland, Perth

Bega Garnbirringu Health Service, Kalgoorlie-Boulder

Laverton Hospital, Laverton

Nickol Bay Hospital, Karratha

Mawarnkarra Health Service, Roebourne

Wirraka Maya Health Service Aboriginal Corporation, South Hedland

Broome Regional Aboriginal Medical Service, Broome

Derby Hospital, Derby

Fitzroy Crossing Hospital, Fitzroy Crossing

Ord Valley Aboriginal Health Service, Kununurra

Halls Creek Health Service, Halls Creek